Identifying in vivo DCE MRI parameters correlated with ex vivo quantitative microvessel architecture: A radiohistomorphometric approach

We introduce a novel radiohistomorphometric method for quantitative correlation and subsequent discovery of imaging markers for aggressive prostate cancer (CaP). While this approach can be employed in the context any imaging modality and disease domain, we seek to identify quantitative dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) attributes that are highly correlated with density and architecture of tumor microvessels, surrogate markers of CaP aggressiveness. This retrospective study consisted of five Gleason score matched patients who underwent 3 Tesla multiparametric MRI prior to radical prostatectomy (RP). The excised gland was sectioned and quartered with a rotary knife. For each serial section, digitized images of individual quadrants were reconstructed into pseudo whole mount sections via previously developed stitching program. The individual quadrants were stained with vascular marker CD31 and annotated for CaP by an expert pathologist. The stained microvessel regions were quantitatively characterized in terms of density and architectural arrangement via graph algorithms, yielding a series of quantitative histomorphometric features. The reconstructed pseudo whole mount histologic sections were non-linearly co-registered with DCE MRI to identify tumor extent on MRI on a voxel-by-voxel basis. Pairwise correlations between kinetic and microvessel features within CaP annotated regions on the two modalities were computed to identify highly correlated attributes. Preliminary results of the radiohistomorphometric correlation identified 8 DCE MRI kinetic features that were highly and significantly (p<0.05) correlated with a number of microvessel parameters. Most of the identified imaging features were related to rate of washout (Rwo) and initial area under the curve (IAUC). Association of those attributes with Gleason patterns showed that the identified imaging features clustered most of the tumors with primary Gleason pattern of 3 together. These results suggest that Rwo and IAUC may be promising candidate imaging markers for identification of aggressive CaP in vivo.

[1]  W. I. Tseng,et al.  Washout gradient in dynamic contrast‐enhanced MRI is associated with tumor aggressiveness of prostate cancer , 2012, Journal of magnetic resonance imaging : JMRI.

[2]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[3]  John V Frangioni,et al.  New technologies for human cancer imaging. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  George Lee,et al.  Computer-aided prognosis: Predicting patient and disease outcome via quantitative fusion of multi-scale, multi-modal data , 2011, Comput. Medical Imaging Graph..

[5]  A. Madabhushi,et al.  Histopathological Image Analysis: A Review , 2009, IEEE Reviews in Biomedical Engineering.

[6]  D J Collins,et al.  Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis , 2006, Physics in medicine and biology.

[7]  Min-Ying Lydia Su Analyzing DCE-MRI data , 2008 .

[8]  K. Lee,et al.  Cancer Research Campaign , 1991 .

[9]  H. Hricak,et al.  Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer. , 2009, Radiology.

[10]  Fabio Grizzi,et al.  Microvessel density estimate: friend or foe in the light of prostate vascular system complexity? , 2010, World Journal of Urology.

[11]  Fred L. Bookstein,et al.  Principal Warps: Thin-Plate Splines and the Decomposition of Deformations , 1989, IEEE Trans. Pattern Anal. Mach. Intell..

[12]  Henkjan J Huisman,et al.  Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. , 2003, Radiology.

[13]  D. Gleason,et al.  Histologic grading of prostate cancer: a perspective. , 1992, Human pathology.

[14]  Gordon Whiteley,et al.  Bringing diagnostic technologies to the clinical laboratory: Rigor, regulation, and reality , 2008, Proteomics. Clinical applications.

[15]  R Novario,et al.  Microvessel density in prostate carcinoma , 2002, Prostate Cancer and Prostatic Diseases.

[16]  Jorge S Reis-Filho,et al.  Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry , 2010, Breast Cancer Research.

[17]  Anant Madabhushi,et al.  HistoStitcher©: An interactive program for accurate and rapid reconstruction of digitized whole histological sections from tissue fragments , 2011, Comput. Medical Imaging Graph..

[18]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[19]  J. Epstein,et al.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. , 2001, Human pathology.

[20]  R. Lenkinski,et al.  Central gland and peripheral zone prostate tumors have significantly different quantitative imaging signatures on 3 tesla endorectal, in vivo T2‐weighted MR imagery , 2012, Journal of magnetic resonance imaging : JMRI.

[21]  Y. Collan,et al.  Prognostic factors in prostate cancer , 2006, Diagnostic pathology.

[22]  Alan Jackson,et al.  Dynamic contrast-enhanced magnetic resonance imaging in oncology , 2005 .

[23]  Gyan Bhanot,et al.  Computerized Image-Based Detection and Grading of Lymphocytic Infiltration in HER2+ Breast Cancer Histopathology , 2010, IEEE Transactions on Biomedical Engineering.

[24]  Anant Madabhushi,et al.  Cascaded discrimination of normal, abnormal, and confounder classes in histopathology: Gleason grading of prostate cancer , 2012, BMC Bioinformatics.

[25]  Anant Madabhushi,et al.  Multi-kernel graph embedding for detection, Gleason grading of prostate cancer via MRI/MRS , 2013, Medical Image Anal..

[26]  Andrew Janowczyk,et al.  High-Throughput Biomarker Segmentation on Ovarian Cancer Tissue Microarrays via Hierarchical Normalized Cuts , 2012, IEEE Transactions on Biomedical Engineering.

[27]  B. Nicolas Bloch,et al.  An illustration of the potential for mapping MRI/MRS parameters with genetic over-expression profiles in human prostate cancer , 2008, Magnetic Resonance Materials in Physics, Biology and Medicine.

[28]  R. Shah,et al.  Current perspectives on the Gleason grading of prostate cancer. , 2009, Archives of pathology & laboratory medicine.

[29]  Peter L Choyke,et al.  Imaging prostate cancer: a multidisciplinary perspective. , 2007, Radiology.

[30]  Anant Madabhushi,et al.  Multi-field-of-view strategy for image-based outcome prediction of multi-parametric estrogen receptor-positive breast cancer histopathology: Comparison to Oncotype DX , 2011, Journal of pathology informatics.

[31]  Andre Dekker,et al.  Radiomics: the process and the challenges. , 2012, Magnetic resonance imaging.

[32]  Aytekin Oto,et al.  Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays. , 2013, Human pathology.

[33]  P Tiwari,et al.  Multimodal wavelet embedding representation for data combination (MaWERiC): integrating magnetic resonance imaging and spectroscopy for prostate cancer detection , 2012, NMR in biomedicine.

[34]  Philippe Puech,et al.  MRI and surveillance , 2012, Current opinion in urology.

[35]  M. Giger,et al.  Automatic identification and classification of characteristic kinetic curves of breast lesions on DCE-MRI. , 2006, Medical physics.

[36]  A. Oto,et al.  Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. , 2011, AJR. American journal of roentgenology.

[37]  Olivier Gevaert,et al.  Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data--methods and preliminary results. , 2012, Radiology.

[38]  Howard Y. Chang,et al.  Decoding global gene expression programs in liver cancer by noninvasive imaging , 2007, Nature Biotechnology.

[39]  L. Klotz,et al.  Cancer overdiagnosis and overtreatment , 2012, Current opinion in urology.